FDA Accepts Mitsubishi Tanabe Pharma ' s NDA Filing for Edaravone to Treat ALS

OSAKA, Japan, Aug. 30, 2016 /PRNewswire/ -- Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President& Representative Director, CEO: Masayuki Mitsuka), today announced that the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news